Arcutis Biotherapeutics achieved strong financial performance in Q3 2025, with net product revenue reaching $99.2 million, a 122% increase year-over-year. The company reported a net income of $7.4 million, a significant turnaround from a loss in the prior year, driven by increased ZORYVE sales and strategic commercialization efforts.

Arcutis Biotherapeutics reported strong financial results for Q2 2025, driven by significant growth in ZORYVE net product revenue, which increased by 164% year-over-year to $81.5 million. The company also achieved FDA approval for ZORYVE foam 0.3% for scalp and body psoriasis and advanced its pipeline with new study initiations and IND submissions.

Arcutis Biotherapeutics delivered excellent performance in Q1 2025, with net product revenue for ZORYVE reaching $63.8 million, a 196% increase year-over-year. The company reported a net loss of $25.1 million, or $0.20 per basic and diluted share, an improvement from the $35.4 million net loss in the prior year. Demand for ZORYVE continued to grow, solidifying its position as a leading non-steroidal topical treatment.

Arcutis Biotherapeutics demonstrated strong financial performance in Q4 2024, with significant increases in total revenues and net product revenue for ZORYVE, driven by robust demand and strategic market access. The company also made progress in its product pipeline and debt management.

Arcutis Biotherapeutics reported Q3 2024 financial results, featuring a 45% increase in product revenue compared to the previous quarter, driven by strong demand for ZORYVE products and improved gross-to-net adjustments. The company also highlighted key regulatory milestones, including the acceptance of the sNDA for ZORYVE foam and approval in Canada, as well as advancements in their pipeline programs.

Arcutis Biotherapeutics reported a strong second quarter with a 43% sequential increase in sales, driven by physician demand for ZORYVE. The company expanded its market reach through a co-promotion agreement with Kowa Pharmaceuticals and advanced its pipeline with the submission of an sNDA for ZORYVE foam. Additionally, they amended their debt agreement to increase financial flexibility.

Arcutis Biotherapeutics, Inc. reported strong first-quarter performance, driven by the successful launch of ZORYVE foam and continued growth of ZORYVE cream. Total revenues reached $49.6 million, including $21.6 million in product revenue and $28.0 million from collaboration agreements. The company's net loss was $35.4 million, and cash reserves remained strong at $404.5 million.

Arcutis Biotherapeutics, Inc. reported a significant increase in total revenues for Q4 2023, driven by strong demand for ZORYVE® cream. The company also achieved FDA approval for ZORYVE® foam and anticipates a transformational year in 2024 with potential approval for roflumilast cream for atopic dermatitis.

Arcutis Biotherapeutics, Inc. reported financial results for the quarter ended September 30, 2023. The company achieved total revenues of $38.1 million, driven by a 70% increase in ZORYVE net product revenues compared to the previous quarter. The FDA approved ZORYVE for an expanded indication in plaque psoriasis. The company also strengthened its balance sheet with a $100 million follow-on offering.

Arcutis Biotherapeutics reported total revenues of $5.2 million for Q2 2023, with ZORYVE contributing $4.8 million, a 72% increase from Q1 2023. The company's commercial coverage expanded to over 130 million commercial lives in the US, and ZORYVE was launched in Canada. Arcutis had approximately $270 million in cash, cash equivalents, and marketable securities as of June 30, 2023.

Arcutis Biotherapeutics reported net revenues of $2.8 million for ZORYVE in Q1 2023, with prescription growth nearly doubling quarter-over-quarter. The company's NDA for roflumilast foam was accepted by the FDA, and enrollment was completed in the INTEGUMENT-PED trial. Arcutis had approximately $333 million in cash, cash equivalents, and marketable securities.

Arcutis Biotherapeutics, Inc. reported financial results for Q4 and full year 2022. ZORYVE net revenues were $3.0 million for the quarter. The company has a strong financial position with approximately $410 million in cash, cash equivalents, and marketable securities.

Arcutis Biotherapeutics reported product revenues of $0.7 million related to sales of ZORYVE. The company's net loss was $107.7 million, or $1.89 per share. They ended the quarter with approximately $480 million in cash, cash equivalents, and marketable securities.

Arcutis Biotherapeutics reported a net loss of $67.4 million for the quarter ended June 30, 2022. The company received FDA approval for ZORYVE and completed enrollment in INTEGUMENT-1.

Arcutis Biotherapeutics reported a net loss of $64.3 million for the quarter ended March 31, 2022. The company's cash, cash equivalents, and marketable securities totaled approximately $345 million. They are increasing commercial preparations for roflumilast cream and completed enrollment for roflumilast foam trials.

Arcutis Biotherapeutics reported a net loss of $71.3 million for Q4 2021, with cash, cash equivalents, and marketable securities totaling $388.6 million. The company believes its financial resources will fund operations into 2024.

Arcutis Biotherapeutics reported a net loss of $57.0 million for the quarter ended September 30, 2021. The company's cash, cash equivalents, and marketable securities totaled $368.8 million as of September 30, 2021, expected to fund operations well into 2023. The company submitted an NDA for roflumilast cream for plaque psoriasis and initiated a Phase 3 trial for roflumilast foam in scalp and body psoriasis.

Arcutis Biotherapeutics reported a net loss of $42.0 million for the quarter ended June 30, 2021. The company's cash, cash equivalents, and marketable securities totaled $410.9 million as of June 30, 2021, which is expected to fund operations well into 2023. The company is on track to submit NDA and initiated Phase 3 trials.

Arcutis had a productive first quarter of 2021, with positive Phase 3 results for topical roflumilast cream in plaque psoriasis and progress in advancing topical roflumilast foam into Phase 3 development for scalp psoriasis and seborrheic dermatitis. The company's Phase 1/2b study of ARQ-252 in chronic hand eczema did not meet its primary endpoint. Arcutis ended the quarter with a strong financial position, holding over $440 million in cash, cash equivalents, and marketable securities.

Arcutis Biotherapeutics reported a net loss of $34.0 million for Q4 2020, with R&D expenses increasing to $27.4 million due to the initiation of multiple clinical trials. The company's cash, cash equivalents, restricted cash and marketable securities were $286.0 million as of December 31, 2020, which, combined with proceeds from a recent equity offering, is expected to fund operations into 2023.

Arcutis Biotherapeutics reported a net loss of $38.2 million for the quarter ended September 30, 2020. The company's cash, cash equivalents, and marketable securities totaled $189.7 million as of September 30, 2020, and they believe that their current cash, cash equivalents and marketable securities at over $300 million will be sufficient to fund its operations into 2022.